Leerink Partners Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $37
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mike Kratky has initiated coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with an Outperform rating and a price target of $37.
October 16, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics has been given an Outperform rating by Leerink Partners, with a price target of $37.
The Outperform rating from Leerink Partners indicates a positive outlook for PROCEPT BioRobotics. The price target of $37 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100